Foghorn Therapeutics develops therapies aimed at addressing diseases caused by disruptions in the chromatin regulatory system, with a particular emphasis on cancer treatment. Utilizing their proprietary Gene Traffic Control® platform, they strive to understand and manipulate the chromatin to create new potential treatments that could impact over 2.5 million cancer patients. The company champions a culture of "People First, Mission Always," valuing diversity and fostering an inclusive environment where team members' unique perspectives contribute to their scientific endeavors. Foghorn is committed to evidence-based approaches, focusing on rigorous data analysis to guide their research and discovery efforts. Employees are encouraged to collaborate across disciplines and grow within the organization, thereby playing a significant role in advancing innovative therapies for critical health challenges.